Richard A. Heyman

Director, Oric Pharmaceuticals, Inc.; Director, Enliven Therapeutics, Inc.

Bought, 12 months

$0.0M

Sold, 12 months

$0.7M

Companies

Latest trade

Oct 1, 2026

Companies

Oric Pharmaceuticals, Inc.Director −$0.3M Enliven Therapeutics, Inc.Director −$0.4M

Trades

ORIC Sold 6,700 shares at $12.91 · planned $0.1M Oct 1

ORIC Sold 13,100 shares at $12.02 · planned $0.2M Jul 24

ORIC Sold 300 shares at $12.00 · planned $0.0M Jul 6

ELVN Sold 1,230 shares at $26.18 · planned $0.0M Feb 17

ELVN Sold 1,230 shares at $26.75 · planned $0.0M Jan 20

ORIC Sold 6,700 shares at $12.00 · planned $0.1M Jan 16

ELVN Sold 4,285 shares at $25.00 · planned $0.1M Jan 9

ELVN Sold 9,635 shares at $25.03 · planned $0.2M Jan 8

Open-market trades from SEC Form 4 only: no grants, option exercises or gifts. People are matched by the name on their filings, so two people with the same name share this page. For information only — not investment advice.